French AFU Cancer Committee Guidelines – Update 2026–2028: Muscle-invasive bladder tumors (MIBC) - 20/11/26
, Gautier Marcq b, Anne Sophie Bajeot c, Yves Allory d, Delphine Borchiellini e, Paul Sargos f, Priscilla Leon g, Alexandra Masson-Lecomte h, Yann Neuzillet i, François Audenet j, Pierre-Etienne Gabriel k, Evanguelos Xylinas k, Benjamin Pradère g, Doriane Prost l, Constance Thibault m, Thomas Seisen n, Morgan Roupret nAbstract |
Objective |
To update the CCAFU guidelines for the management of muscle-invasive bladder cancer (MIBC).
Methods |
A systematic review (Medline) of the literature from 2024 to 2026 was performed, considering the diagnostic work-up, treatment options, and NMIBC and MIBC follow-up, with references graded according to their level of evidence.
Results |
The diagnosis of muscle-invasive bladder cancer relies on transurethral resection of the bladder. The staging work-up includes CT urography combined with chest CT. Multiparametric bladder MRI may be proposed to refine locoregional assessment without delaying management. For nonmetastatic disease, radical cystectomy with standard pelvic lymph node dissection remains the reference treatment. In cisplatin-eligible patients, a perioperative strategy based on cisplatin-based neoadjuvant chemotherapy should be discussed, with consideration of integrating immunotherapy and perioperative systemic treatment according to available indications. The combination of enfortumab vedotin and pembrolizumab (EVP) is also recommended. In cisplatin-ineligible patients, EVP represents a major therapeutic option when available. A bladder-sparing strategy using trimodal therapy—combining maximal transurethral resection, external beam radiotherapy, and concomitant radiosensitizing chemotherapy—should be discussed and offered to selected, well-informed patients who are compliant with rigorous follow-up. Urinary diversion by enterocystoplasty may be offered to both men and women in the absence of oncologic, functional, or general contraindications; otherwise, ileal conduit urinary diversion remains the reference diversion. Enrollment in an enhanced recovery program after surgery is recommended for all surgical patients. For metastatic disease, the EVP combination is the recommended first-line treatment. After disease progression, subsequent therapeutic options should be tailored according to previously received treatments, patient profiles, potential molecular alterations, and access to clinical trials.
Conclusion |
This update of the CCAFU guidelines aims to harmonize and optimize the management of patients with muscle-invasive bladder cancer, incorporating recent developments in diagnostic work-up, perioperative treatments, bladder-preservation strategies, and the management of metastatic disease.
Le texte complet de cet article est disponible en PDF.Keywords : Urothelial carcinoma, Bladder neoplasms, Cancer, Cystectomy, Survival
Plan
Vol 36 - N° 11
Article 103192- janvier 2026 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
